AstraZeneca’s Benralizumab Study: Real-World Insights in China

AstraZeneca ((AZN)) announced an update on their ongoing clinical study.

Study Overview: AstraZeneca is conducting a non-interventional study titled A Multicentre, Single Arm, Non-interventional, Prospective Study to Assess Demographic Characteristics and Patient Reported Outcomes in Patients With Severe Eosinophilic Asthma Treated With Benralizumab in China. The study aims to gather data on the clinical profile and therapeutic efficacy of benralizumab in patients aged 12 and above with severe eosinophilic asthma. It will assess early treatment response, outcomes, and changes in asthma control in a real-world setting, while also exploring reasons for therapy discontinuation or switching.

Intervention/Treatment: The study focuses on benralizumab, a non-interventional treatment. Benralizumab is intended to improve asthma control in patients with severe eosinophilic asthma by targeting and reducing eosinophils, which are inflammatory cells involved in asthma.

Study Design: This is an observational cohort study with a prospective time perspective. It is non-interventional, meaning it observes outcomes without altering the treatment regimen. The study does not involve allocation or masking, focusing instead on real-world data collection.

Study Timeline: The study began on March 3, 2025, with the latest update submitted on September 4, 2025. These dates are crucial as they mark the study’s initiation and the most recent data collection, indicating ongoing progress.

Market Implications: This study could influence AstraZeneca’s stock performance by providing insights into benralizumab’s effectiveness in a real-world setting, potentially boosting investor confidence. Positive outcomes may enhance AstraZeneca’s competitive position in the respiratory treatment market, particularly in China, where severe eosinophilic asthma is a significant concern.

The study is currently recruiting, with further details available on the ClinicalTrials portal.